Small-molecule PIK-93 modulates the tumor microenvironment to improve immune checkpoint blockade response

Immune checkpoint inhibitors (ICIs) targeting PD-L1 immunotherapy are state-of-the-art treatments for advanced non–small cell lung cancer (NSCLC). However, the treatment response of certain patients with NSCLC is unsatisfactory because of an unfavorable tumor microenvironment (TME) and poor permeabi...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Chia-Yi, Huang, Kuo-Yen, Kao, Shih-Han, Lin, Ming-Shiu, Lin, Chih-Chien, Yang, Shuenn-Chen, Chung, Wei-Chia, Chang, Ya-Hsuan, Chein, Rong-Jie, Yang, Pan-Chyr
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2023
Materias:
Biomedicine and Life Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10081850/
https://www.ncbi.nlm.nih.gov/pubmed/37027467
http://dx.doi.org/10.1126/sciadv.ade9944

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10081850/
https://www.ncbi.nlm.nih.gov/pubmed/37027467
http://dx.doi.org/10.1126/sciadv.ade9944

Ejemplares similares